London’s health and care system hampering STP progress, finds report

London’s “complex and cluttered” health and care system is holding back plans to improve the health of its population, finds a new independent report from The King’s Fund.

Read on PharmaTimes

AZ/MSD’s Lynparza assigned Orphan status in US

AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.

Read on PharmaTimes

Another Humira biosimilar hits EU shores

Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.

Read on PharmaTimes

UK launch for first eosinophilic oesophagitis drug

Dr Falk Pharma has launched Jorveza - the first globally licensed drug approved for eosinophilic oesophagitis - across the UK.

Read on PharmaTimes

Pfizer’s Talzenna cleared for breast cancer

US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.

Read on PharmaTimes

1 2 3

Top of page

Industry News

London’s “complex and cluttered” health and care system is holding back plans to improve the health of its population, finds...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us